Overview
Corporate Profile

CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer.

CytRx's initial focus is on seeking regulatory approval for and commercialization of our lead drug candidate, aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin. Aldoxorubicin is currently in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, and is also being evaluated in several other cancer indications with significant unmet clinical need, including small-cell lung cancer.

Cyt... More >>

Stock Chart
Stock chart for: 03NA000000CYTR
Upcoming Events
DateTitle
07/12/17 10:00 a.m. PT
CytRx Annual Meeting of Shareholders
LocationHotel Bel Air
701 Stone Canyon Rd.
Los Angeles, CA 90077
Recent Releases
DateTitle 
06/13/17CytRx Announces Reshaping of Clinical and Regulatory Executive TeamPrinter Friendly Version
06/08/17CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue SarcomasPrinter Friendly Version
05/17/17CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual MeetingPrinter Friendly Version
05/10/17CytRx Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
Some more press releases >
Stock Quote
CYTR (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$0.69
Change (%)0.00 (0.00%)
Volume0
Data as of 06/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Reports
 PDF2016 10-K
 PDF2017 Proxy Statement
 PDFLetter to Shareholders: May 22, 2017
Contact Information
David Haen
CytRx Corporation
Vice President, Business Development and Investor Relations
(310) 826-6498
dhaen@cytrx.com

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.